Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01164163 · ClinicalTrials.gov registry record · Phase 1
INCB18424 in Treating Young Patients With Relapsed or Refractory Solid Tumor, Leukemia, or Myeloproliferative Disease
A Phase 1 study of Leukemia and Myelodysplastic Syndromes, sponsored by Children's Oncology Group.
- Completed
- Registry status
- Phase 1
- Development phase
- 49
- Enrollment target
- 20
- Study locations
NCT01164163: Completed Phase 1 study of Leukemia and Myelodysplastic Syndromes, sponsored by Children's Oncology Group.
NCT01164163 is a Phase 1 study of Leukemia and Myelodysplastic Syndromes that has completed, run by Children's Oncology Group. The registered enrollment target is 49 participants, below the 487-participant average among 233 other Leukemia trials with a reported enrollment target (90% lower). The trial reports 20 study locations across 17 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01164163, a Phase 1 study of Leukemia and Myelodysplastic Syndromes, has completed, sponsored by Children's Oncology Group.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 49 participants
- Enrollment target
- 20
- Study locations
Study Summary
RATIONALE: INCB18424 (Ruxolitinib) may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase 1 clinical trial is studying the side effects and best dose of INCB18424 in treating young patients with relapsed or refractory solid tumor, leukemia, or myeloproliferative disease.
Conditions Studied
Interventions
- OTHER laboratory biomarker analysis
- OTHER pharmacological study
- DRUG ruxolitinib phosphate
Study Locations (20)
California
- Children's Hospital of Orange County - Orange
- UCSF Helen Diller Family Comprehensive Cancer Center - San Francisco
Maryland
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins - Baltimore
- Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office - Bethesda
Pennsylvania
- Children's Hospital of Philadelphia - Philadelphia
- Children's Hospital of Pittsburgh of UPMC - Pittsburgh
Alabama
- UAB Comprehensive Cancer Center - Birmingham
Colorado
- Children's Hospital Colorado Center for Cancer and Blood Disorders - Aurora
District of Columbia
- Children's National Medical Center - Washington D.C.
Georgia
- AFLAC Cancer Center and Blood Disorders Service of Children's Healthcare of Atlanta - Egleston Campus - Atlanta
Illinois
- Children's Memorial Hospital - Chicago - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49 participants |
| Start Date | 2010-09 |
| Phase | Phase 1 |
What the finished NCT01164163 record still lists
NCT01164163 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 49 participants, a relatively small participant target, below the 487-participant average among 233 other Leukemia trials with a reported enrollment target (90% lower).
The record links to 5 conditions, with Leukemia appearing as the primary indexed condition, and to 3 interventions - of which laboratory biomarker analysis is the first listed.
NCT01164163 names 20 study sites across 17 states, led by California, Maryland, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT01164163 about?
NCT01164163 is a clinical study titled "INCB18424 in Treating Young Patients With Relapsed or Refractory Solid Tumor, Leukemia, or Myeloproliferative Disease". RATIONALE: INCB18424 (Ruxolitinib) may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase 1 clinical trial is studying the side effects and best dose of INCB18424 in treating young patients with relapsed or refractory solid tumor, leukemia, o...
What is the current status of trial NCT01164163?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 49 participants. The study started on 2010-09.
What conditions does trial NCT01164163 study?
This clinical trial studies the following conditions: Leukemia, Myelodysplastic Syndromes, Chronic Myeloproliferative Disorders, Myelodysplastic/Myeloproliferative Neoplasms, Unspecified Childhood Solid Tumor, Protocol Specific.
What interventions are being tested in trial NCT01164163?
The interventions under investigation include: laboratory biomarker analysis (OTHER), pharmacological study (OTHER), ruxolitinib phosphate (DRUG).
Who is sponsoring clinical trial NCT01164163?
This trial is sponsored by Children's Oncology Group, which has 342 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01164163 being conducted?
This trial has 20 study locations across Alabama, California, Colorado, District of Columbia, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01164163's enrollment target sits among peer trials
49 117th of 233 higher than 116 of 233 other Leukemia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Leukemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Revumenib in Combination With 7+3 + Midostaurin in AML
RECRUITING · Phase 1
-
CIML NK Cells With Venetoclax for AML
RECRUITING · Phase 1
-
A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: A Phase 1/2 Study of Tagraxofusp, Azacitidine, and Venetoclax
RECRUITING · Phase 1
-
Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL)
RECRUITING · Phase 1
-
A Prospective Trial of Dalbavancin-Based Prophylaxis in Children and Adolescents With High-Risk Leukemia
RECRUITING · Phase 1
-
Venetoclax and Chemotherapy as Frontline Therapy in Older Patients and Patients With Relapsed/Refractory ALL
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02704858 · 49 participants · Phase 1
Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma
- NCT03516708 · 49 participants · Phase 1
Epacadostat (INCB024360) Added to Preoperative Chemoradiation in Patients With Locally Advanced Rectal Cancer
- NCT03692429 · 49 participants · Phase 1
alloSHRINK - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells
- NCT04329494 · 49 participants · Phase 1
PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia